Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection Versus Conventional Antiplatelet Therapy After Complex Percutaneous Coronary Intervention: The PRECISE-PCI Randomized Clinical Trial

NCT06283888 is registered in ClinicalTrials.gov with Zunyi Medical College as lead sponsor.

NCT NCT06283888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06283888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection Versus Conventional Antiplatelet Therapy After Complex Percutaneous Coronary Intervention: The PRECISE-PCI Randomized Clinical Trial
Lead sponsor
Zunyi Medical College
Phase
Phase 4
Overall status
Recruiting
Start date
April 1, 2024
Completion date
December 1, 2028
Enrollment
1,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acs - acute coronary syndrome, cyp2c19 polymorphism